Find Your Funding Opportunity
Notice of Intent to Publish a Funding Opportunity Announcement for Morris K. Udall Discovery Centers without Walls (DCWoW) for Parkinson\'s Disease Research (RM1 - Clinical Trial Optional)
Service
|
Source |
Final Application Due Date |
Funding Available
|
Match Required
|
|---|---|---|---|---|
| Health Care |
Federal
HHS |
03-14-2025 | N/A | No Match Required |
-
Service
-
Source
-
Final Application Due Date
-
Funding Available
-
Match Required
Status
- Opportunity Type Discretionary
-
CFDA
93.853 -- Extramural Research Programs in the Neurosciences and Neurological Disorders
Description
The National Institute of Neurological Disorders and Stroke (NINDS) intends to promote team science research to discover the causes of Parkinson's Disease by publishing a Notice of Funding Opportunity (NOFO) to solicit applications for Morris K. Udall Discovery Centers without Walls (DCWoW) for Parkinson's Disease Research. Parkinson�s disease (PD) is a chronic, progressive movement disorder that affects the lives of at least half a million people across the United States (US), as well as having significant impact on the relatives and friends who care for them. The average onset of characteristic motor symptoms, which are initially subtle and increasingly impact purposeful movement, most often occurs in the sixth decade of life; onset at much younger ages is also possible. Persons with PD also experience a broad range of non-motor symptoms including autonomic dysfunction (e.g. constipation, urinary incontinence, orthostatic hypotension, sexual dysfunction), sleep disturbances, pain, changes in mood, and cognitive dysfunction potentially leading to dementia. Available pharmacological and surgical treatments provide limited relief from some motor symptoms but fail to address non-motor symptoms or attenuate the ultimate progression of the disease. A clear cause and definitive cure have remained elusive despite important biomedical research advances, such as the identification of environmental and genetic risk factors. As our population ages, the number of persons with PD is projected to increase significantly; a 2022 technical brief by the World Health Organization (WHO) stated that global burden, including disability and mortality due to PD, are increasing at a more rapid rate compared with other neurological diseases. The NINDS is the primary Federal funder for PD research in the US, providing support for investigator-initiated projects as well as dedicated programs including the NINDS Morris K. Udall Centers of Excellence for PD Research, the NINDS PD Biomarkers Program (PDBP) and the public-private Accelerating Medicines Partnership for PD (AMP PD). In recognition of the impact of PD on our society, and to advance NINDS-supported research into the causes of PD, this initiative expands the NINDS Udall Centers program to promote biomedical discovery through an innovative, integrated team science approach. This Notice encourages investigators with expertise, insights, and innovative approaches in the area of Parkinson's disease and related synucleinopathies to begin to consider applying for this new NOFO. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.� The NOFO is expected to be published in autumn 2024 with an expected application due date in early spring 2025. This NOFO will utilize the RM1 activity code. Details of the planned NOFO are provided below.
Eligibility
- IHE
- Local Government
- Non-Profit
- Other
- State Government
- Tribal Government
Key Date(s)
- August 26, 2024: Forecasted Date
- November 01, 2024: Estimated Post Date
- March 14, 2025: Estimated Application Due Date
- December 01, 2025: Estimated Project Start Date
- December 01, 2025: Estimated Award Date